Filing Flows

Filing Flows › Krystal Biotech (KRYS) › Next earnings date

Krystal Biotech (KRYS) earnings: beat the estimate

Krystal Biotech (KRYS) reported on Nov 2, 2026 and beat the EPS estimate: $2.05 against $1.92 (+6.9%). Revenue was $127M for Q3 2026, +30% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+6.9% vs estimate
Beat rate80%

The last report

Krystal Biotech reported revenue of $127M for the third quarter 2026 (+30% Y/Y), net earnings $63.1M. How it makes money → · Every quarter →

Krystal Biotech: EPS against the estimate, last 5 reportsKrystal Biotech: EPS against the estimate, last 5 reportsEstimateReported$1.12$2.66Nov 25$1.61$1.70Feb 26$1.42$1.83May 26$1.91$1.79Aug 26$1.92$2.05Nov 26
Latest (Nov 26): Estimate $1.92, Reported $2.05.

Krystal Biotech's latest quarter

Krystal Biotech, Q3 2026: revenue $127M (+30% year over year), operating margin 55.9%, net earnings $63.1M, operating cash flow $91.2M. The chart follows the revenue to costs, profit and cash.

Questions

Did Krystal Biotech beat earnings?

Krystal Biotech (KRYS) reported on Nov 2, 2026 and beat the EPS estimate: $2.05 against $1.92 (+6.9%).

When does KRYS report earnings?

The next date is not set yet.

Does Krystal Biotech usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.